Raymond James Begins Coverage on Aquestive Therapeutics (NASDAQ:AQST)

Analysts at Raymond James assumed coverage on shares of Aquestive Therapeutics (NASDAQ:AQST) in a research note issued on Thursday, Marketbeat Ratings reports. The brokerage set an “outperform” rating and a $7.00 price target on the stock. Raymond James’ target price would suggest a potential upside of 70.73% from the stock’s previous close.

AQST has been the subject of several other research reports. JMP Securities lifted their price objective on shares of Aquestive Therapeutics from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Friday, March 15th. HC Wainwright lifted their price objective on shares of Aquestive Therapeutics from $7.00 to $9.00 and gave the stock a “buy” rating in a research note on Monday, March 18th.

Aquestive Therapeutics Stock Up 1.0 %

Shares of Aquestive Therapeutics stock opened at $4.10 on Thursday. Aquestive Therapeutics has a twelve month low of $0.82 and a twelve month high of $6.23. The company has a 50-day simple moving average of $3.49 and a two-hundred day simple moving average of $2.41. The stock has a market capitalization of $300.53 million, a price-to-earnings ratio of -29.28 and a beta of 2.85.

Insider Buying and Selling at Aquestive Therapeutics

In other Aquestive Therapeutics news, insider Alexander Mark Schobel sold 50,000 shares of the firm’s stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $6.00, for a total value of $300,000.00. Following the transaction, the insider now directly owns 984,476 shares of the company’s stock, valued at approximately $5,906,856. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 8.39% of the company’s stock.

Institutional Investors Weigh In On Aquestive Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Armistice Capital LLC grew its holdings in shares of Aquestive Therapeutics by 314.5% during the 3rd quarter. Armistice Capital LLC now owns 4,800,000 shares of the company’s stock valued at $7,344,000 after purchasing an additional 3,642,000 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Aquestive Therapeutics by 11.2% during the 4th quarter. Vanguard Group Inc. now owns 1,889,053 shares of the company’s stock valued at $3,816,000 after purchasing an additional 190,401 shares during the last quarter. Renaissance Technologies LLC grew its holdings in Aquestive Therapeutics by 137.1% during the 2nd quarter. Renaissance Technologies LLC now owns 1,230,196 shares of the company’s stock worth $2,030,000 after acquiring an additional 711,396 shares during the last quarter. Millennium Management LLC grew its holdings in Aquestive Therapeutics by 326.2% during the 2nd quarter. Millennium Management LLC now owns 1,108,764 shares of the company’s stock worth $709,000 after acquiring an additional 848,584 shares during the last quarter. Finally, Essex Investment Management Co. LLC bought a new stake in Aquestive Therapeutics during the 4th quarter worth approximately $1,709,000. 32.45% of the stock is owned by institutional investors.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.